Beat C. Bornhauser

Zurich, ZH, Switzerland

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 79 publications

Drugging smart: molecular glue degraders rise in T-ALL.

Drugging smart: molecular glue degraders rise in T-ALL.

Journal: Blood
Published: August 06, 2026

Tripping the switch: p38 inhibition unlocks venetoclax and inotuzumab ozogamicin synergy.

Tripping the switch: p38 inhibition unlocks venetoclax and inotuzumab ozogamicin synergy.

Journal: Haematologica
Published: July 15, 2026

TCF3::HLF orchestrates an enhancer-promoter network with activation of MEF2C to promote immature HSC gene expression in leukemia.

TCF3::HLF orchestrates an enhancer-promoter network with activation of MEF2C to promote immature HSC gene expression in leukemia.

Journal: Science advances
Published: May 06, 2026

A clinical-stage oncology compound selectively targets drug-resistant cancers.

A clinical-stage oncology compound selectively targets drug-resistant cancers.

Journal: bioRxiv : the preprint server for biology
Published: December 15, 2025

Functional precision approach in patients with very high risk acute lymphoblastic leukaemia in India: a single-centre cohort study.

Functional precision approach in patients with very high risk acute lymphoblastic leukaemia in India: a single-centre cohort study.

Journal: The Lancet regional health. Southeast Asia
Published: September 12, 2025

IGH::FENDRR and specific KRAS mutations define a novel B-ALL molecular subtype with poor chemotherapy response.

IGH::FENDRR and specific KRAS mutations define a novel B-ALL molecular subtype with poor chemotherapy response.

Journal: Blood
Published: August 14, 2025

Intra-subtype heterogeneity shapes treatment response in KMT2A-rearranged ALL across all age groups.

Intra-subtype heterogeneity shapes treatment response in KMT2A-rearranged ALL across all age groups.

Journal: HemaSphere
Published: August 14, 2025

IGH::FENDRR and specific KRAS mutations define a novel B-ALL molecular subtype with poor chemotherapy response.

IGH::FENDRR and specific KRAS mutations define a novel B-ALL molecular subtype with poor chemotherapy response.

Journal: Blood
Published: August 14, 2025

Transcriptional remodeling shapes therapeutic vulnerability to necroptosis in acute lymphoblastic leukemia.

Transcriptional remodeling shapes therapeutic vulnerability to necroptosis in acute lymphoblastic leukemia.

Journal: Blood
Published: February 28, 2025

Co-editing of NKG2A and FAS increases long-term cytotoxic capacity and persistence of CAR NK cells.

Co-editing of NKG2A and FAS increases long-term cytotoxic capacity and persistence of CAR NK cells.

Journal: Molecular therapy. Oncology
Published: January 31, 2025

A three-dimensional ex vivo model recapitulates in vivo features and drug resistance phenotypes in childhood acute lymphoblastic leukemia.

A three-dimensional ex vivo model recapitulates in vivo features and drug resistance phenotypes in childhood acute lymphoblastic leukemia.

Journal: Leukemia
Published: January 22, 2025

Caspase-2 kills cells with extra centrosomes.

Caspase-2 kills cells with extra centrosomes.

Journal: Science advances
Published: October 30, 2024
Showing 1-12 of 79

Last Updated: 09/26/2026